Physician profile
April E Cotton
NPI 1710922398
$3,546.53
in general payments reported to CMS, 2019-2025
29 companies · $780 in 2025
The $780 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $621 · 2020: $188 · 2021: $167 · 2022: $491 · 2023: $704 · 2024: $596 · 2025: $780.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,080.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,079.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $617.64 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $519.55 | 2022-2025 | Vraylar, Ubrelvy, Linzess |
| Astrazeneca Pharmaceuticals LP | $384.22 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $341.43 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $326.26 | 2019-2024 | Mounjaro, Zepbound, Trulicity |
| Pfizer INC. | $324.45 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $194.74 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $101.64 | 2020-2023 | |
| Dexcom, INC. | $69.80 | 2023-2025 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $63.11 | 2020-2023 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.80 | 2022-2025 | Xifaxan |
| Abiomed | $53.50 | 2024 | Impella |
| Abbott Laboratories | $49.36 | 2025 | Freestyle Libre 3 |
| Idorsia Pharmaceuticals US INC | $44.49 | 2023-2024 | Quviviq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $42.31 | 2025 | Caplyta |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $38.39 | 2022-2023 | |
| Phathom Pharmaceuticals, INC. | $37.47 | 2024-2025 | Voquezna |
| Exact Sciences Corporation | $34.80 | 2025 | Cologuard Collection Kit |
| Mannkind Corporation | $32.08 | 2023 | Afrezza |
| Allergan, INC. | $30.09 | 2019-2020 | |
| Amgen INC. | $26.99 | 2019-2022 | |
| Mylan Specialty L.P. | $26.48 | 2020-2024 | Yupelri |
| Astellas Pharma US INC | $24.93 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $24.62 | 2022 | |
| Verona Pharma, INC. | $22.74 | 2025 | Ohtuvayre |
| Novartis Pharmaceuticals Corporation | $21.46 | 2023 | |
| Biohaven Pharmaceuticals, INC. | $11.76 | 2021 | |
| Janssen Pharmaceuticals, INC | $11.06 | 2019 | |
| Organon LLC | $10.36 | 2025 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw April Cotton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.